Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years

Novo Nordisk and Eli Lilly lead the weight loss market with GLP-1 drugs, but face competition from Roche. Roche's upcoming GLP-1 weight loss drugs show promise, potentially challenging the market leaders. Investors should monitor Roche's development in the competitive landscape.